HIV-1 group O phenotypic susceptibility to integrase inhibitors

International audienc

Next Generation Sequencing Analysis of HIV-1 Group O Reverse Transcriptase Residue 181C Prevalence and Evolution over Time, With or Without Antiretroviral Selection Pressure

International audienc

Mise au point d'une méthode de quantification de l'ARN plasmatique spécifique des VIH-1 de groupe M

International audienc

HIV-1 group P infection: towards a dead-end infection?

HIV/1 group P (HIV-1/P) is the last HIV/1 group discovered and to date, comprises only two strains. To obtain new insights into this divergent group, we screened for new infections by developing specific tools, and analysed phenotypic and genotypic properties of the prototypic strain RBF168. In addition, the follow-up of the unique patient monitored so far, has raised the knowledge of the natural history of this infection and its therapeutic management. We developed an HIV-1/P specific sero-molecular strategy and screened over 29,498 specimen samples. Infectivity and evolution of the gag-30 position, considered as marker of adaptation to human, were explored by successive passages of RBF168 strain onto human PBMCs. Natural history and immuno-virological responses to combined antiretroviral therapy (cART) were analysed based on CD4 counts and plasmatic viral load evolution. No new infection was detected. Infectivity of RBF168 was found lower, relative to other main HIV groups and the conservative methionine found in the gag-30 position revealed a lack of adaptation to human. The follow-up of the patient during the five-year ART-free period, showed a relative stability of CD4 cell count with a mean of 326 mm. Initiation of cART led to rapid RNA undetectability with a significant increase of CD4, reaching 687 mm after 8 years. Our results showed that HIV-1/P strains remain extremely rare and could be less adapted and pathogenic than other HIV strains. These data lead to the hypothesis that HIV-1/P infection could evolve towards, or even already correspond to, a dead-end infection

Mais KES-C-K'C un organoïde ?

Ce media a été produit dans un but de vulgarisation de la Sciences des travaux de recherche fondamentale menés par les chercheurs de la fédération hospitalo-universitaire RESPIRE (FHU RESPIRE). Il est hébergé sur la chaîne youtube de la FHU RESPIRE et a été réalisé dans un cadre strictement professionn

Une journée en immersion dans un laboratoire Covid-19

The conversationAlors que désormais chacun connaît la PCR comme outil de diagnostic de la COVID-19, savez-vous ce que signifie l’acronyme « PCR » ? Comment ce test fonctionne-t-il en pratique ?Cet article a pour objectif de vous ouvrir les portes d’un laboratoire dédié à la détection du SARS-CoV2, agent responsable de la COVID19. Vous découvrirez ainsi le quotidien, heure par heure, des équipes qui prennent en charge les prélèvements, réalisent chaque jour des centaines de PCR pour transmettre un résultat de diagnostic. Vous comprendrez le fonctionnement du test PCR et la coopération des nombreux acteurs de santé (préleveur, technicien de laboratoire, biologiste médical…) qui participent au défi que représente ce diagnostic.Ainsi la PCR SARS-CoV2 n’aura plus de secret pour vous

Fièvre de la vallée du Rift : diagnostic d'une arbovirose peu classique en France métropolitaine, à ne pas méconnaître !

International audienc

Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches

International audienc

Virological response to integrase strand transfer inhibitor-based antiretroviral combinations in HIV-1 group O-infected patients

International audienceAlthough integrase strand transfer inhibitors (INSTIs) are widely used in HIV-1 group M (HIV-1/M) infections, little is known about their efficacy against genetically divergent HIV-1 group O (HIV-1/O) strains. Previous phenotypic works have demonstrated the variable susceptibility of HIV-1/O strains, depending on INSTI drugs. Clinical data are very limited and obtained from a few patients.OBJECTIVES:To investigate the virological success rate of an INSTI-based combination of antiretroviral therapy (cART) in a large population of HIV-1/O-infected patients, and to describe resistance-associated mutations (RAM) at virological failure.METHODS:The virological response of 39 patients receiving INSTI-based cART during their follow-up was analysed i) at the last point of the first INSTI initiation and ii) at their most recent visit. RAM analysis was performed at virological failures. Resistance interpretation was based on the French National Agency of Research on AIDS and viral hepatitis (ANRS) rules.RESULTS:Virological success at both time points of analysis was high, with more than 87% of the patients with undetectable plasma viral load. Among the six patients with virological failure, three selected RAM described for HIV-1/M resistance, and two had already RAM, before INSTI initiation.CONCLUSION:Our results show that HIV-1/O infected patients receiving INSTI-based cART presented a high rate of virological success whatever their previous lines; we have also shown that resistance rules for HIV-1/M could be considered when failure occurs. These data are of importance especially in the context of WHO recommendations for a wider use of this class

Le séquençage des variants du Covid expliqué par ses spécialistes

The Conversatio